Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
Fed Regist. 1998 Dec 14; 63(239):68710-2.FR

Abstract

The Food and Drug Administration (FDA) is proposing to amend its regulations governing investigational new drug applications (IND's) for human drug and biological products. This proposed action would amend the IND clinical hold requirements to state that the agency will respond in writing to a sponsor's request that a clinical hold be removed from an investigation within 30-calendar days of the agency's receipt of the request and the sponsor's complete response to the issue(s) that led to the clinical hold. This proposed action is being taken in accordance with provisions of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act). This proposed rule is a companion document to a direct final rule published elsewhere in this issue of the Federal Register. If FDA receives any significant adverse comment, the direct final rule will be withdrawn, and the comments will be considered in the development of a final rule using usual notice-and-comment rulemaking based on this proposed rule.

MeSH

Drug ApprovalDrugs, InvestigationalPolicy MakingUnited StatesUnited States Food and Drug Administration

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10187560

Citation

"Investigational New Drug Applications; Clinical Holds; Companion Document to Direct Final rule--FDA. Proposed Rule." Federal Register, vol. 63, no. 239, 1998, pp. 68710-2.

Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule. Fed Regist. 1998;63(239):68710-2.

(1998). Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule. Federal Register, 63(239), 68710-2.

Investigational New Drug Applications; Clinical Holds; Companion Document to Direct Final rule--FDA. Proposed Rule. Fed Regist. 1998 Dec 14;63(239):68710-2. PubMed PMID: 10187560.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule. PY - 1998/11/16/pubmed PY - 1998/11/16/medline PY - 1998/11/16/entrez SP - 68710 EP - 2 JF - Federal register JO - Fed Regist VL - 63 IS - 239 N2 - The Food and Drug Administration (FDA) is proposing to amend its regulations governing investigational new drug applications (IND's) for human drug and biological products. This proposed action would amend the IND clinical hold requirements to state that the agency will respond in writing to a sponsor's request that a clinical hold be removed from an investigation within 30-calendar days of the agency's receipt of the request and the sponsor's complete response to the issue(s) that led to the clinical hold. This proposed action is being taken in accordance with provisions of the Food and Drug Administration Modernization Act of 1997 (the Modernization Act). This proposed rule is a companion document to a direct final rule published elsewhere in this issue of the Federal Register. If FDA receives any significant adverse comment, the direct final rule will be withdrawn, and the comments will be considered in the development of a final rule using usual notice-and-comment rulemaking based on this proposed rule. SN - 0097-6326 UR - https://www.unboundmedicine.com/medline/citation/10187560/Investigational_new_drug_applications DB - PRIME DP - Unbound Medicine ER -

Tags

Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.Fed Regist. 1998 Dec 14; 63(239):68710-2.FR